Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 5/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147659 | 0.92 | RET (0.48) | RETKDM5ACTSAGRM5P2RX7 | |
| SCHEMBL20069611 | 0.86 | RET (0.49) | RETKDM5ACTSAGRM5PTPN11 | |
| SCHEMBL20147623 | 0.81 | RET (0.46) | RETKDM5ACTSAGRM5P2RX7 | |
| SCHEMBL20147655 | 0.79 | RET (0.48) | RETP2RX7 | |
| SCHEMBL20147656 | 0.79 | RET (0.49) | RETP2RX7PTPN11 | |
| SCHEMBL20147936 | 0.76 | RET (0.47) | RETP2RX7 | |
| SCHEMBL20147644 | 0.75 | RET (0.42) | RETKDM5ACTSAGRM5PTPN11 | |
| SCHEMBL20069182 | 0.75 | RET (0.48) | RETCTSAGRM5 | |
| SCHEMBL20068978 | 0.73 | RET (0.49) | RETPTPN11 | |
| SCHEMBL20069110 | 0.73 | RET (0.42) | RETKDM5ACTSAGRM5P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885KDM5A 902/4885CTSA 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.